^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Meningioma

    Related cancers:
    2d
    A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    Mechanistic studies suggest that this missense mutation may abnormally activate the MAPK signaling pathway, which is implicated in the pathogenesis of tumor progression and neurodevelopmental disorders. This is the first reported case of a germline mutation in the SMARCB1 gene associated with both CSS3 and meningioma, thereby expanding the phenotypic spectrum of SMARCB1-related disorders.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    SMARCB1 mutation
    3d
    A Shotgun Proteomic-Based Approach with a Q-Exactive Hybrid Quadrupole-Orbitrap High-Resolution Mass Spectrometer for the Assessment of Pesticide Mixture-Induced Neurotoxicity on a 3D-Developed Neurospheroid Model from Human Brain Meningiomas: Identification of Trityl-Post-Translational Modification. (PubMed, J Proteome Res)
    The study also highlights the plausible role of pyrethroids to be implicated in the deleterious effects of pesticides in a mixture. To the best of our knowledge, our finding is the first in toxicoproteomics to deeply elucidate pesticides' molecular interactions and their ability to adduct proteins as a pivotal role in the neurotoxicity mechanism.
    Journal
    |
    GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
    4d
    Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Scott R. Plotkin, MD, PhD | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    NF2 (Neurofibromin 2)
    |
    Nerlynx (neratinib) • Alunbrig (brigatinib)
    5d
    Presenting characteristics and clinical outcomes of idiopathic versus neurofibromatosis type 2-associated spinal meningiomas: a retrospective institutional experience. (PubMed, J Neurosurg Spine)
    In this study of 166 surgically treated patients with SM, patients with NF2 presented earlier, experienced earlier progression, and experienced progression more frequently compared with those without NF2. Radiographic characteristics of tumors were relatively consistent between groups. While idiopathic SMs remain a relatively benign and highly manageable disease, considering tumor molecular characteristics and broader clinical history is paramount in providing efficacious and individualized patient care.
    Clinical data • Retrospective data • Journal
    |
    NF2 (Neurofibromin 2)
    |
    NF2 mutation
    5d
    Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations (AIOM 2024)
    4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. The incidence of targettable molecular alterations in adult CNS tumor patients was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.
    Clinical • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • POLE (DNA Polymerase Epsilon) • MDM2 (E3 ubiquitin protein ligase) • PTCH1 (Patched 1) • NF2 (Neurofibromin 2) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • TMB-H • PIK3CA mutation • MET amplification • ALK rearrangement • FGFR1 amplification • POLE mutation • NF1 mutation • MDM2 amplification • RET mutation • PTCH1 mutation • NF2 mutation • ROS1 mutation • BRCA mutation • ALK rearrangement + PIK3CA mutation • PTCH1 rearrangement • NTRK fusion
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Alecensa (alectinib) • Erivedge (vismodegib)
    7d
    Intracranial angioleiomyoma mimicking meningioma: an uncommon tumor with favorable outcome and frequent GJA4 mutation. (PubMed, Neurosurg Rev)
    IALM had favorable outcome. Notably, IALMs frequently exhibited a GJA4 mutation, which was linked to the cavernous sinus and orbital locations, as well as PR expression.
    Journal
    |
    PGR (Progesterone receptor) • GJA4 (Gap Junction Protein Alpha 4)
    |
    PGR expression
    8d
    Differential Expression of Proteins and Genes at the Tumor-Brain Interface in Invasive Meningioma. (PubMed, Genes Chromosomes Cancer)
    Pathway analyses identified significant links between DTX1 and RASGRF1 and key biological processes, including cell-cell adhesion, and signaling pathways including Notch, RAS, MAPK, and Rho. Higher expression of DTX1, RASGRF1, and Ki-67 in the brain-invasive area of meningiomas suggests that these proteins play a role in the process of brain invasion.
    Journal
    |
    IL6 (Interleukin 6) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1)
    12d
    Clinical study on the protective effect of preoperative lumbar drainage on the temporal lobe in petroclival meningioma resection by anterior transpetrous approach (ChiCTR2400090537)
    P=N/A, N=160, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital Capital Medical University
    New trial
    14d
    Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    15d
    Detection of CDKN2A/B homozygous deletion by DNA methylation and DNA next generation sequencing: a comparison (SNO 2024)
    All cases of homozygous deletion detected by NGS were also detected by DNA methylation. DNA methylation derived copy number assessment is more sensitive for CDKN2A/B homozygous deletion than next generation sequencing.
    Next-generation sequencing • Epigenetic controller
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion
    |
    NYU Langone Genome PACT assay
    15d
    Proton Radiation For Meningiomas and Hemangiopericytomas (clinicaltrials.gov)
    P1/2, N=53, Completed, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Completed
    Trial completion
    17d
    BAH2472: TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Essen Biotech | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV
    21d
    MicroRNA Analysis in Meningiomas with Different Degrees of Tissue Stiffness: A Potential Tool for Effective Preoperative Planning. (PubMed, Neurosurgery)
    This research highlights the potential of miRNAs as biomarkers for determining meningioma tissue stiffness. Identifying specific miRNAs associated with tumor consistency could improve preoperative planning and patient prognosis. These findings pave the way for further exploration of miRNAs in the clinical assessment of meningiomas.
    Journal
    |
    MIR31 (MicroRNA 31) • MIR34B (MicroRNA 34b)
    22d
    Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE (clinicaltrials.gov)
    P4, N=20, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    26d
    H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications. (PubMed, Cancers (Basel))
    Comprehending the role of H3K27me3 in CNS tumors is vital for advancing diagnostic tools and therapeutic interventions, with the goal of enhancing patient outcomes and quality of life. This review underscores the importance of ongoing investigations into H3K27me to refine and optimize management strategies for CNS tumors, paving the way for improved personalized medicine practices in oncology.
    Review • Journal
    |
    H3-3A (H3.3 Histone A)
    28d
    Immunohistochemical Expression of Tenascin-C in Canine Meningiomas. (PubMed, Vet Sci)
    The reaction to TN-C was more significant in grade II and III tumors. The immunohistochemical findings of the current study suggest that TN-C can act as a stromal marker, mainly in grade II or III meningiomas.
    Journal
    |
    VIM (Vimentin)
    28d
    Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Patients with Advanced Meningioma: Initial Safety and Efficacy. (PubMed, J Nucl Med)
    It may result in improved radiologic and clinical disease control compared with intravenous PRRT. Further research to validate these initial findings and to investigate long-term outcomes is highly warranted.
    Journal • Metastases
    |
    SSTR (Somatostatin Receptor)
    30d
    Multiomic and clinical analysis of multiply recurrent meningiomas reveals risk factors, underlying biology, and insights into evolution. (PubMed, Sci Adv)
    MRM recurrences were found to be similar to primaries but have a greater burden of copy number gains (P < 0.0001) and increased methylation (P = 0.0045). This clinical and multiomic investigation of MRMs harbors implications for the future development of biomarkers and therapeutic agents for these challenging tumors.
    Journal
    |
    EDNRB (Endothelin Receptor Type B)
    30d
    Spine Stereotactic Radiosurgery Provides Long-Term Local Control and Overall Survival for Benign Intradural Tumors. (PubMed, Neurosurgery)
    With long-term follow-up, spine radiosurgery is a safe and effective treatment for benign intradural tumors. In carefully selected patients, even with an NF1 mutation, SRS is associated with a high likelihood of local tumor control.
    Journal • Surgery
    |
    NF1 (Neurofibromin 1)
    |
    NF1 mutation
    1m
    Current state of spinal nerve sheath tumor management and future advances. (PubMed, Neurooncol Adv)
    Though surgery is the traditional mainstay of treatment for these tumors, the discovery of the genetic and molecular basis of these diseases in recent decades has prompted investigation into targeted therapies. Here, we give a clinical overview of spinal nerve sheath tumors, their imaging features, current management practices, and explore ongoing advances in systemic therapies.
    Review • Journal
    |
    NF2 (Neurofibromin 2)
    1m
    Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1 trial
    1m
    Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (clinicaltrials.gov)
    P2, N=25, Recruiting, Fundación de investigación HM | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    1m
    Giant Intracranial Meningiomas Requiring Surgery in 2 Transgender Women Treated With Cyproterone Acetate. (PubMed, JCEM Case Rep)
    Our cases highlight the real-world risk of this likely underreported adverse effect and underscore the importance of clinician vigilance for neurological sequelae. We suggest using the lowest dose of CPA that maintains adequate androgen suppression, with consideration of alternative anti-androgens where appropriate.
    Journal • Surgery
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    cyproterone acetate
    1m
    Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2. (PubMed, Dis Model Mech)
    Collectively, these findings highlight the generation of a novel zebrafish model that mimics the complexities of the human NF-2 disorder. Consequently, this model holds significant potential for facilitating therapeutic screening and elucidating key driver genes implicated in NF-2 onset.
    Journal
    |
    NF1 (Neurofibromin 1) • NF2 (Neurofibromin 2)
    |
    NF2 mutation
    1m
    Astroblastoma: A molecularly defined entity, its clinico-radiological & pathological analysis of eight cases and review of literature. (PubMed, Pathol Res Pract)
    They typically carry a favorable prognosis. High level suspicion is required for their diagnosis and molecular analysis is must to distinguish them from other morphological mimics.
    Review • Journal
    |
    MN1 (MN1 Proto-Oncogene Transcriptional Regulator) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    1m
    MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas. (PubMed, Cancers (Basel))
    P16 expression was variable and did not correlate with either MTAP expression or CDKN2A FISH results. MTAP IHC is a promising surrogate marker for the evaluation of CDKN2A status in meningiomas.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    1m
    BAH2472: TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (clinicaltrials.gov)
    P1/2, N=85, Not yet recruiting, Essen Biotech
    New P1/2 trial • Metastases
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV
    1m
    Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands. (PubMed, J Nucl Med)
    No abstract available
    Journal
    |
    SSTR (Somatostatin Receptor)
    1m
    Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4. (PubMed, Neurooncol Adv)
    In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas. Our results shed new insight into the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.
    Journal
    |
    NF2 (Neurofibromin 2) • YAP1 (Yes associated protein 1) • FAT3 (FAT Atypical Cadherin 3) • VGLL4 (Vestigial Like Family Member 4)
    |
    NF2 mutation
    1m
    Exophthalmos as the initial presentation of metastatic prostate cancer. (PubMed, Radiol Case Rep)
    Histopathological examination after biopsy of the left orbit showed adenocarcinoma of the prostate. This case substantiates the diverse clinical and radiological presentations of metastatic prostate cancer and underscores the diagnostic significance of targeted biopsy.
    Journal • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    1m
    Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. (PubMed, Oncoimmunology)
    Both, AdFITC(E2)-CAR T-cell tumor infiltration and biocidal activity were Octo-Fluo concentration-dependent, with high doses of Octo-Fluo, saturating both the CAR and the SSTR2 antigen independently, leading to the loss of tumor infiltration and biocidal activity due to the loss of bridge formation. Our findings demonstrate the potential of using AdFITC(E2)-CAR T-cells with Octo-Fluo as a versatile, on-off tunable bispecific adaptor for targeted CAR T-cell immunotherapy against SSTR2-positive NETs.
    Journal • CAR T-Cell Therapy
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 expression • SSTR2 positive
    2ms
    SEL-TH-1601: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (clinicaltrials.gov)
    P2, N=10, Completed, Children's Hospital Medical Center, Cincinnati | Suspended --> Completed | Trial completion date: Jun 2025 --> May 2024 | Trial primary completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    NF2 (Neurofibromin 2)
    |
    NF2 mutation
    |
    Koselugo (selumetinib)
    2ms
    Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival. (PubMed, Radiat Oncol)
    Re-irradiation presents a viable option for recurrent anaplastic meningioma despite the associated risk of radiation necrosis. Higher doses with concomitant Bevacizumab improve clinical outcomes and reduce toxicity. Individualized treatment approaches are necessary, emphasizing the importance of further research to refine management strategies for this challenging disease.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion
    |
    Avastin (bevacizumab)
    2ms
    Application of carbonic anhydrase IX in sporadic hemangioblastoma of the central nervous system and hemangioblastoma associated with von Hippel-Lindau disease. (PubMed, Clin Neuropathol)
    Hemangioblastoma might be diagnosed with high specificity and sensitivity through CAIX immunohistochemistry. The combination of CAIX with EMA is useful for the diagnosis and differential diagnosis of hemangioblastoma.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    CA9 expression
    2ms
    Lenticulostriatal Ischemia Shows Relevant SSTR Expression on PET/CT Imaging Using the Novel SSTR-Targeting Peptide 18F-SiTATE. (PubMed, Clin Nucl Med)
    Moreover, there was focal 18F-SiTATE uptake in the left caudate and corresponding contrast enhancement due to postischemic blood-brain barrier disruption and reactive SSTR expression. Therefore, increased cortical or subcortical SSTR PET signal may be related to ischemic changes even in the subacute stage after initial stroke.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    2ms
    Posterior pituitary tumors and other rare entities involving the pituitary gland. (PubMed, Brain Pathol)
    If meningiomas, craniopharyngiomas, and germ cell tumors are excluded, the remaining lesions include a broad spectrum of uncommon, benign, and aggressive, often diagnostically challenging lesions. This review aims to summarize the essential clinicopathological features of tumors of the posterior pituitary gland, infundibulum spectrum expressing thyroid transcription factor 1, and primary sellar atypical rhabdoid teratoid tumor, and provide the criteria for their diagnosis and management.
    Review • Journal
    |
    NKX2-1 (NK2 Homeobox 1)
    2ms
    Blood and cerebrospinal fluid biomarkers in neuro-oncology. (PubMed, Curr Opin Neurol)
    This review summarizes the current knowledge and future perspectives of liquid biopsy of blood and CSF for diagnosis and monitoring of primary CNS tumors.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TERT (Telomerase Reverse Transcriptase) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMO (Smoothened Frizzled Class Receptor) • KLF4 (Kruppel-like factor 4)
    |
    EGFR mutation • PTEN mutation • MYD88 L265P • NF2 mutation • TERT mutation • SMO mutation • TERT promoter mutation
    2ms
    Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (clinicaltrials.gov)
    P2, N=104, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    Stivarga (regorafenib)
    2ms
    Hybrid Somatostatin Receptor PET/MRI of the Head and Neck. (PubMed, Radiographics)
    Radiologists should be aware of the advantages of somatostatin receptor PET/MRI in evaluation of head and neck tumors as well as the potential pitfalls of this approach so that they can accurately advise clinicians and better interpret these studies.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    2ms
    Novel therapies for pediatric low grade glioma. (PubMed, Curr Opin Neurol)
    Historical treatment options in pediatric low-grade gliomas have utilized surgery, radiation therapy and conventional chemotherapy. Recently greater insight into their biology has found that alterations in MAPK driven pathways are often the hallmark of tumorigenesis. Targeting these novel pathways has led to tumor control and shrinkage without the use of conventional chemotherapy. Caution should be taken however, since these treatment options are still novel, and we do not fully appreciate the long-term effects. Nonetheless a new era of targeted medicine is here.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR (Fibroblast Growth Factor Receptor) • NTRK (Neurotrophic receptor tyrosine kinase) • PRKCA (Protein Kinase C Alpha)
    |
    BRAF V600E • BRAF V600 • FGFR fusion • BRAF fusion • ROS1 mutation • ROS1 amplification • NTRK fusion
    2ms
    DATUM: Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma (clinicaltrials.gov)
    P=N/A, N=11, Not yet recruiting, Central Hospital, Nancy, France
    New trial
    |
    Lutathera (lutetium Lu 177 dotatate)
    2ms
    SSTR: Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, Central Hospital, Nancy, France | Trial completion date: Jul 2024 --> Mar 2025 | Initiation date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Jan 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)